I
IONS
Ionis Pharmaceuticals, Inc. Common Stock
$42.70
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Ionis Pharmaceuticals, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$3.47
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$1.23
Oct 27
Posts
No posts about IONS yet.
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals designs RNA-targeting drugs, called antisense oligonucleotides, that block disease-causing proteins before the body can make them. The company earns revenue two ways: selling its own approved medicines directly, and collecting licensing fees and royalty payments from larger drugmakers like Novartis and Biogen, who market Ionis-discovered therapies for conditions ranging from heart disease to rare neurological disorders.